AMGN vs NBIX
Figures are each company’s own, from its most recent annual filing; fiscal year ends differ. Both are classified by the SEC under Biological Products, (No Diagnostic Substances).
| Metric | AMGNAMGEN INC | NBIXNEUROCRINE BIOSCIENCES INC |
|---|---|---|
| Revenue | $36.75B | $2.86B |
| Gross margin | 67.2% | 98.2% |
| Operating income | $9.08B | $619.10M |
| Operating margin | 24.7% | 21.6% |
| Net income | $7.71B | $478.60M |
| Net margin | 21.0% | 16.7% |
| Free cash flow | $8.10B | $748.70M |
| Total assets | $90.59B | $4.63B |
| Total equity | $8.66B | $3.25B |
| Diluted EPS | $14.23 | $4.67 |
Every figure links to the filing it came from on each company page: AMGN and NBIX. See the methodology for how each one is chosen.